Cellectis to Announce Q3 2025 Financial Results on November 7

Cellectis SA ( (CLLS) ) just unveiled an update.

On October 31, 2025, Cellectis announced that it will release its third-quarter financial results for 2025 on November 7, 2025, after the US market closes. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance during the quarter. Notably, Cellectis will not host a conference call to discuss these results, but its investor relations team is available for inquiries.

The most recent analyst rating on (CLLS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.

Spark’s Take on CLLS Stock

According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.

Cellectis SA’s overall stock score is driven by its strong technical momentum and positive developments from the earnings call, including strategic partnerships and clinical trial progress. However, financial performance challenges and valuation concerns due to ongoing losses and lack of dividend yield weigh down the score.

To see Spark’s full report on CLLS stock, click here.

More about Cellectis SA

Cellectis is a clinical-stage biotechnology company that utilizes a pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology, offering off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment. With in-house manufacturing capabilities, Cellectis manages the entire cell and gene therapy value chain. Headquartered in Paris, France, with locations in New York and Raleigh, NC, Cellectis is listed on the Nasdaq Global Market and Euronext Growth.

Average Trading Volume: 146,083

Technical Sentiment Signal: Buy

Current Market Cap: $254.7M

See more data about CLLS stock on TipRanks’ Stock Analysis page.